Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

Contagion Live News Network: Does ACE2 Explain COVID-19 Pediatric Incidence?

MAY 28, 2020 | CONTAGION® EDITORIAL STAFF

Transcript:

Hello and thank you for joining Contagion. I’m here with a brief on our latest infectious disease clinical coverage:

A new study found that children have less angiotensin-converting enzyme 2 (ACE2) in nasal epithelium than older populations, which might confer some protection against SARS-CoV-2 entering cells at this vulnerable site for infection and transmission, and explain their lower incidence of coronavirus 2019 (COVID-19).

The current trials testing broad-spectrum antibiotics before treating tuberculosis are not aligned with protocols designed to minimize the use of antibiotics, according to a paper published in The Lancet Infectious Diseases.

Investigators from London conducted a review and meta-analysis in order to organize available evidence on the diagnostic performance of the trial of antibiotics for tuberculosis. They wrote that there are suboptimal diagnostics for the infection and broad-spectrum antibiotics are given to patients who test negative but remain symptomatic, typically to try and identify tuberculosis vs. a lower respiratory tract infection.

And as a reminder: Contagion’s June print edition is on its way. In his June letter, titled “COVID-19 Preprints: Reader, Beware”, our editor-in-chief Dr. Jason Gallagher explored the proliferation of preprints amid the ongoing rush to publish information during the COVID-19 pandemic.
 
For more on these stories and the latest infectious disease news, visit contagionlive.com. Thanks for watching.
 
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?